EpistemisPainful erythropathy due to cold Raynaud-like agglutinin
Specialty: Hematology.
Why it occurs
- Primary cryoagglutinemia (production of IgM monoclonal antibodies that agglutinate erythrocytes in cold temperatures)
- Cryoglobulinemia type II and III of monoclonal or polyclonal origin (associated with lymphoproliferative processes, myeloma or autoimmune diseases such as Sjögren's syndrome, where insoluble proteins precipitate upon exposure to cold, temporarily obstructing the terminal arterial capillaries)
- Antiphospholipid antibody syndrome with cold-induced distal microangiopathy
- Chronic graft-versus-host disease in hematopoietic stem cell transplant recipients
- Raynaud's phenomenon secondary to scleroderma or systemic connective tissue diseases with circulating cold antibodies.
Initial workup
Quantitative determination of serum cryoglobulins (requires collection of the blood sample and centrifugation strictly maintained at 37 °C to avoid in vitro precipitation of the analyte) with subsequent characterization by immunofixation; erythrocyte sedimentation rate (ESR), which usually shows falsely zero or extremely low values if the sample is cooled, and extremely high values at body temperature; prewarmed peripheral blood smear to evaluate agglutination or rouleaux phenomena; serum complement C3 and C4 levels (typically decreased by consumption in active cryoglobulinemia); complete serologies for hepatitis C and hepatitis B viruses; nail bed capillaroscopy to evaluate microvascular morphology.
red flags
Appearance of established digital necrosis with the presence of hemorrhagic flictenae, local anesthesia or stony coldness in the pads of the fingers or toes that does not respond to gradual passive rewarming; continuous persistent and lacerating ischemic pain that requires management with infusion of major opioid analgesics; development of dyspnea at rest and reflex tachycardia along with frank macroscopic hematuria (acute intravascular hemolytic crisis due to uncontrolled activation of systemic complement).
Standard management
- Rituximab — monoclonal antibody directed against CD20; pillar of the treatment of choice by eliminating the clones of B lymphocytes that produce pathological cryoglobulins or cold agglutinins
- Nifedipine — prolonged-release oral vasodilator calcium antagonist; reduces the distal vascular spastic component and improves microvascular tissue perfusion in extremities exposed to low temperatures
- Prednisone — systemic glucocorticoid for the inflammatory management of associated cryoglobulinemic vasculitis
- Therapeutic plasmaplasmapheresis (indicated in severe cases with progressive digital ischemia or acute renal involvement to immediately purify cryoglobulins from the bloodstream, mandatory performed in a heated circuit).
Educational guidance for study. It is NOT a prescription recommendation. The actual choice depends on the cause, the patient, and current guidelines.
- Area
- Hematology
- Listed causes
- 5
- Treatment options
- 4